| Literature DB >> 30458837 |
L Cavazzana1, M Fornili2, G Filocamo3, C Agostoni2,3, F Auxilia4,5, S Castaldi4,6.
Abstract
BACKGROUND: Juvenile idiopathic arthritis (JIA) is the most common pediatric chronic rheumatic disease, which requires constant follow-up over the years, due to relapses during its progression. To maintain a good quality of life, it is important to limit admissions as far as possible. With the development of a Diagnostic Therapeutic Assistance Pathway (DTAP), we aim to select patients with suitable clinical conditions to be moved from routine hospital management to day care or outpatient treatment, evaluating the number of patients to whom this would apply.Entities:
Keywords: Diagnostic therapeutic assistance pathway (DTAP); Juvenile idiopathic arthritis (JIA); Pediatrics; Quality of life
Mesh:
Year: 2018 PMID: 30458837 PMCID: PMC6245695 DOI: 10.1186/s13052-018-0576-8
Source DB: PubMed Journal: Ital J Pediatr ISSN: 1720-8424 Impact factor: 2.638
Fig. 1DTAP flowchart
Characteristics of the patients
| Variable | |
|---|---|
| Age, years, median (IQR) | 9 (5–13) |
| Gender, | |
| Female | 102 (80) |
| Male | 25 (20) |
| Residence, | |
| Milan metropolitan area | 66 (52) |
| Rest of Lombardy | 44 (35) |
| Other regions | 17 (13) |
| Patients whose admissions are eligible for DTAP, | |
| No admission | 57 (45) |
| Some admissions | 29 (23) |
| All admissions | 41 (32) |
DTAP diagnostic therapeutic assistance pathway, IQR interquartile range
Results of univariable Firth’s logistic regression: inclusion in the DTAP versus patients and hospitalization characteristics
| Variable | All ( | Non DTAP ( | DTAP ( | OR (95% CI) |
|
|---|---|---|---|---|---|
| Condition on admission, | |||||
| Not good | 40 (18) | 40 (31) | 0 (0) | ||
| Good | 183 (82) | 91 (69) | 92 (100) | ||
| Fever on admission, n (%) | |||||
| No | 207 (88) | 115 (88) | 92 (100) | ||
| Yes | 16 (7) | 16 (12) | 0 (0) | ||
| Sedation, | |||||
| No | 133 (60) | 41 (31) | 92 (100) | ||
| Yes | 90 (40) | 90 (69) | 0 (0) | ||
| Age, years, median (IQR) | 10 (6–14) | 10 (5–14) | 10 (6–13) | 1.01 (0.96–1.06) | 0.70 |
| Gender, | 0.10 | ||||
| Male | 54 (24) | 37 (28) | 17 (18) | reference | |
| Female | 169 (76) | 94 (72) | 75 (82) | 1.71 (0.91–3.32) | |
| Residence, | 0.001 | ||||
| Lombardy | 198 (89) | 124 (95) | 74 (80) | reference | |
| Other regions | 25 (11) | 7 (5) | 18 (20) | 4.12 (1.74–10.7) | |
| Discharge JIA diagnosis, | 0.12* | ||||
| Oligoarticular | 84 (38) | 47 (37) | 37 (41) | reference | |
| Polyarticular | 76 (35) | 43 (34) | 33 (36) | 0.98 (0.52–1.82) | 0.94 |
| Systemic | 33 (15) | 26 (20) | 7 (8) | 0.36 (0.14–0.86) | 0.02 |
| Enthesitis-related | 9 (4) | 5 (4) | 4 (4) | 1.04 (0.26–3.91) | 0.96 |
| Monoarticular | 9 (4) | 3 (2) | 6 (7) | 2.35 (0.62–10.4) | 0.21 |
| Psoriatic | 8 (4) | 4 (3) | 4 (4) | 1.27 (0.31–5.22) | 0.74 |
| Unknown | 4 | 3 | 1 | ||
| Urgent admission, | 0.008 | ||||
| No | 201 (90) | 112 (85) | 89 (97) | reference | |
| Yes | 22 (10) | 19 (15) | 3 (3) | 0.20 (0.06–0.66) | |
| Transfer from other hospital, | 0.34 | ||||
| No | 218 (98) | 127 (97) | 91 (99) | reference | |
| Yes | 5 (2) | 4 (3) | 1 (1) | 0.35 (0.04–3.06) | |
| First hospitalization, | 0.37 | ||||
| No | 196 (88) | 113 (86) | 83 (90) | reference | |
| Yes | 27 (12) | 18 (14) | 9 (10) | 0.68 (0.29–1.58) | |
| Length of stay, days, median (IQR) | 6 (3–8) | 6 (3–9) | 6 (3–7) | 0.95 (0.89–1.01) | 0.11 |
| Cause of hospitalization, | < 0.0001* | ||||
| Flare | 79 (35) | 44 (34) | 35 (38) | reference | |
| Arthrocentesis | 47 (21) | 45 (34) | 2 (2) | 0.07 (0.01–0.22) | < 0.0001 |
| Investigations for suspected JIA | 45 (20) | 28 (21) | 17 (18) | 0.77 (0.36–1.61) | 0.49 |
| Clinical and therapeutic re-evaluation | 16 (7) | 6 (5) | 10 (11) | 2.02 (0.70–6.22) | 0.19 |
| Associated conditions | 10 (4) | 6 (5) | 4 (4) | 0.87 (0.22–3.09) | 0.83 |
| Biologic therapy | 24 (11) | 0 (0) | 24 (26) | 61.4 (8.03–7894) | < 0.0001 |
| Arthrocentesis and biological therapy | 2 (1) | 2 (2) | 0 (0) | 0.25 (0.00–3.21) | 0.32 |
| Electrocardiogram, | 0.002 | ||||
| No | 58 (26) | 24 (18) | 34 (37) | reference | |
| Yes | 164 (74) | 106 (82) | 58 (63) | 0.39 (0.21–0.71) | |
| Unknown | 1 | 1 | 0 | ||
| Ultrasound, | 0.08 | ||||
| No | 65 (29) | 44 (34) | 21 (23) | reference | |
| Yes | 158 (71) | 87 (66) | 71 (77) | 1.69 (0.93–3.13) | |
| X-rays, | 0.01 | ||||
| No | 98 (44) | 67 (51) | 31 (34) | reference | |
| Yes | 125 (56) | 64 (49) | 61 (66) | 2.04 (1.19–3.56) | |
| Nuclear magnetic resonance, | 0.66 | ||||
| No | 191 (86) | 111 (85) | 80 (87) | reference | |
| Yes | 32 (14) | 20 (15) | 12 (13) | 0.84 (0.39–1.79) | |
| Computed tomography, | 0.69 | ||||
| No | 219 (98) | 129 (98) | 90 (98) | reference | |
| Yes | 4 (2) | 2 (2) | 2 (2) | 1.43 (0.22–9.42) | |
| Positron emission tomography, | 0.20 | ||||
| No | 220 (99) | 128 (98) | 92 (100) | reference | |
| Yes | 3 (1) | 3 (2) | 0 (0) | 0.20 (0.00–2.08) | |
| Eye examination, | 0.09 | ||||
| No | 100 (45) | 65 (50) | 35 (38) | reference | |
| Yes | 123 (55) | 66 (50) | 57 (62) | 1.60 (0.93–2.75) | |
| Cardiac examination, | 0.19 | ||||
| No | 101 (45) | 64 (49) | 37 (40) | reference | |
| Yes | 121 (55) | 66 (51) | 55 (60) | 1.44 (0.84–2.47) | |
| Unknown | 1 | 1 | 0 | ||
| Anesthesiology examination, | < 0.0001 | ||||
| No | 127 (57) | 42 (32) | 85 (92) | reference | |
| Yes | 96 (43) | 89 (68) | 7 (8) | 0.04 (0.02–0.09) | |
| Orthognatodontic examination, | 0.08 | ||||
| No | 182 (82) | 112 (85) | 70 (76) | reference | |
| Yes | 41 (18) | 19 (15) | 22 (24) | 1.84 (0.94–3.65) | |
| Orthopedic examination, | 0.009 | ||||
| No | 193 (87) | 120 (92) | 73 (79) | reference | |
| Yes | 30 (13) | 11 (8) | 19 (21) | 2.78 (1.29–6.26) | |
| Dermatological examination, | 0.70 | ||||
| No | 209 (94) | 122 (93) | 87 (95) | reference | |
| Yes | 14 (6) | 9 (7) | 5 (5) | 0.81 (0.26–2.34) | |
| Otorhinolaryngology examination, | 0.76 | ||||
| No | 221 (99) | 130 (99) | 91 (99) | reference | |
| Yes | 2 (1) | 1 (1) | 1 (1) | 1.43 (0.11–17.8) | |
| Physical therapy, | 0.96 | ||||
| No | 70 (31) | 41 (31) | 29 (32) | reference | |
| Yes | 153 (69) | 90 (69) | 63 (68) | 0.99 (0.56–1.76) | |
| Arthrocentesis, | < 0.0001 | ||||
| No | 114 (51) | 43 (33) | 71 (77) | reference | |
| Yes | 109 (49) | 88 (67) | 21 (23) | 0.15 (0.08–0.27) | |
| Intravenous therapy, | < 0.0001 | ||||
| No | 104 (47) | 24 (18) | 80 (87) | reference | |
| Yes | 119 (53) | 107 (82) | 12 (13) | 0.04 (0.02–0.07) | |
DTAP diagnostic therapeutic assistance pathway, JIA juvenile idiopathic arthritis, IQR interquartile range, OR odds ratio, CI confidence interval
*Global likelihood ratio test p-value
Fig. 2First two dimensions plane from the multiple corresponding analysis. Categorical variables: anesthesiology examination (anesthesiology), arthrocentesis, cardiac examination (cardiac), cause of hospitalization (cause), length of stay, electrocardiogram (ECG), eye examination (eye), fever on admission (fever), first hospitalization (first), good condition on admission (good condition), intravenous therapy (IV), nuclear magnetic resonance (NMR), orthognatodontic examination (OG), orthopedic examination (orthopedic), residence outside Lombardy region (distant), physical therapy (PT), sedation, ultrasound (US), urgent admission (urgent), X-rays. Eligibility to the diagnostic therapeutic care pathway (DTAP) is passively projected to the plane as a supplementary variable. The percentage of total variability explained by each axis is reported. Other abbreviations: JIA = juvenile idiopathic arthritis; N = no; Y = yes
Intermediate Pediatric Care Unit’s activity data about patients with JIA
| Activity/year | 2014 | 2015 | 2016 |
|---|---|---|---|
| First examination | 152 | 201 | 165 |
| Follow-up | 524 | 613 | 585 |
| Mac10 | 175 | 193 | 222 |
| Hospitalization | 89 | 66 | 68 |
MAC Complex Outpatient Macroactivity with High Resource Integration (an organizational model, set up by the Lombardy Region, relating the management of all the activities that could be done outpatient)